Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Shirley Wang (NPI 1598831026)

Field	Value
Entity Type	Individual
Organization	Shirley Wang
Address	8101 College Blvd Ste 100
City	Overland Park
State	KS
ZIP	66210
Taxonomy	Rheumatology Physician
NPI Enumerated	November 27, 2006

Payer Source	Total Paid
Medicare	$1.2M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is the clear revenue driver: total Medicare revenue is $1.2M while there is no Medicaid billing on file, so the practice is effectively single‑payer (Medicare) in the public programs captured here. Analysts should treat Medicaid as absent when modeling payer mix or population coverage for this NPI.

Revenue is highly concentrated in a small set of biologic infusion and injectable drug codes: the precomputed top three Medicare codes account for 64.3% of total Medicare revenue, driven by J0717 ($384K), J0129 ($253.3K) and J1602 ($143K). That concentration indicates the practice’s financial performance is closely tied to a handful of high‑cost injectable therapies.

The CPT/HCPCS mix is consistent with a rheumatology practice that provides in‑office administration of biologic therapies and infusion services: high revenue entries include J0717 (certolizumab pegol), J0129 (abatacept), J1602 (golimumab) as well as infliximab codes Q5104 ($139.8K) and J1745 ($139.6K). Supporting procedure codes for drug administration and infusion (96413, 96401, 96415) and multiple injectable drug codes show the practice operates an infusion/administration workflow rather than relying solely on self‑administered treatments.

Competitive standing across the major biologic codes is mixed: J0717 ranks #157 of 848 (82nd percentile) and is within a broadly typical national volume band for that code, J0129 ranks #682 of 1221 (44th percentile) and J1602 ranks #531 of 1041 (49th percentile), both showing modest or mid‑range participation compared with peers. By contrast, the biosimilar infliximab code Q5104 ranks #22 of 178 (88th percentile), which places this provider among the higher national users of that specific biosimilar within a relatively small cohort of reporting providers.

Service intensity in office visits is an outlier relative to national peers: 99215 shows 452 claims, $124 avg paid/claim, $56K revenue (4.6% of Medicare revenue) and ranks #2464 of 145531 providers nationally (98th percentile; extreme outlier, far above typical national volume for this code). This suggests a disproportionate share of high‑complexity office E/M encounters — consistent with a complex, medically intensive patient panel or a practice pattern that documents higher‑level visits.

Infusion and chemotherapy administration codes appear regularly but are characterized in the data as typical volumes relative to national peers: 96413 (390 claims, $37.1K; ranks #1190 of 7514, 84th percentile — typical, unremarkable), 96401 (479 claims, $25.9K; ranks #282 of 3868, 93rd percentile — typical, unremarkable), and 96415 (242 claims, $5.1K; ranks #404 of 4959, 92nd percentile — typical, unremarkable). Taken together with the high‑revenue biologic drug codes, these administration codes corroborate an infusion‑capable practice profile without signaling anomalous administration volume by the provided labels.

Tenure and stability: the NPI was enumerated on 2006-11-27 (~20 years ago), indicating a long‑standing presence in the market that can support steady referral relationships and repeat biologic infusion business. This longevity is relevant when projecting continuity of care and likely ongoing Medicare revenue.

From a payer‑strategy perspective, the absence of Medicaid billing means the provider’s publicly reported revenue exposure is concentrated in Medicare; payers and network planners should not assume Medicaid access or experience without separate contractual or claims evidence. Given the concentration in a few high‑revenue biologic codes, any contracting or utilization‑management discussion should prioritize those specific drugs and their administration pathways.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

14 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	96,000	$1	$384K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	7,450	$30	$253.3K
J1602	Injection, golimumab, 1 mg, for intravenous use	13,000	$10	$143K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	4,820	$30	$139.8K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	5,370	$30	$139.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	450	$120	$56K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	390	$100	$37K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	480	$50	$25.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	190	$80	$16.1K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	80	$150	$11.7K

Showing 1–10 of 14

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 14 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Shirley Wang — 3 of 14 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

14 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	10	20	8,000	$30	$291.5K
J0717	1	10	51,600	$1	$200.4K
J1602	10	20	14,360	$10	$167.7K
Q5104	1	10	4,820	$30	$139.9K
J1745	8	20	3,110	$30	$96.9K
96413	22	80	80	$90	$26.3K
99214	1,654	4,310	120	$70	$16.4K
96401	1	30	180	$50	$9K
99215	19	1,350	40	$100	$8.4K
99205	81	560	30	$140	$6K

Showing 1–10 of 14

Related Providers

Other providers that share a Tax Identification Number (TIN) with Shirley Wang, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0
Shaker Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Shirley Wang, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Maxim Healthcare Services, Inc.	KS	Home Health Agency	$0	$64.4M
Laboratory Corporation Of America Holdings	KS	Clinical Medical Laboratory	$8.5M	$26.1M
Maxim Healthcare Services,inc.	KS	Home Health Agency	$0	$23.5M
Moore Enterprises	KS	Home Health Agency	$0	$16M
Carestaf, Inc.	KS	Home Health Agency	$0	$10.4M
Laboratory Corporation Of America Holdings	KS	Clinical Medical Laboratory	$806.3K	$6.6M
Intelligere LLC	KS	Interpreter	$0	$6.5M
Homestead Of Overland Park Operations LLC	KS	Assisted Living Facility	$0	$2.4M
In Home Family Counseling Associates LLC	KS	Marriage & Family Therapist	$0	$1.8M
Vpa PC	KS	Family Medicine Physician	$0	$1.2M

Shirley Wang — Billing Profile & Reimbursement Data

Sign up for Shirley Wang — Billing Profile & Reimbursement Data policy alerts

Shirley Wang — Billing Profile & Reimbursement Data

Sign up for Shirley Wang — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References